title: Benefit of FOLFOX to unresectable liver metastases secondary from colorectal carcinoma in an oncologic emergency.
abstract: Liver metastasis is an important prognostic factor in colorectal cancer. The efficacy of resection of metastatic lesions in liver metastasis of colorectal cancer is also widely recognized. However, studies on treatment methods of unresectable cases have not been sufficient and obtaining complete remission (CR) for liver metastasis is rare with chemotherapy. Selection of reliable chemotherapy for unresectable liver metastasis is an urgent necessity. The usefulness of oxaliplatin, 5-flurouracil and leucovorin combination therapy (FOLFOX) has recently been reported, but CR of liver metastasis is rare. The current status and new therapeutic significance of FOLFOX therapy are discussed based on the literature of colorectal cancer chemotherapy to date, and the clinical experience in which we obtained CR for liver metastasis is reported. The patient had stage IV rectal cancer, perforative peritonitis, pelvic abscess and simultaneous multiple liver metastasis. The patient underwent an emergency operation using the Hartmann's procedure. Liver metastasis is considered to be a prognostic factor and FOLFOX was selected as the postoperative chemotherapy, CR of the liver metastasis was obtained. FOLFOX was suggested to have new clinical significance in oncologic emergencies against unresectable liver metastasis in colorectal cancer and should serve as adjuvant chemotherapy that will contribute to improvement of treatment results.
authors.affiliation: Department of Surgery, Teikyo University Chiba Medical Center, Chiba, Japan. sugimoto@med.teikyo-u.ac.jp
authors.forename: Maki
authors.initials: M
authors.lastname: Sugimoto
authors.forename: Hideki
authors.initials: H
authors.lastname: Yasuda
authors.forename: Keiji
authors.initials: K
authors.lastname: Koda
authors.forename: Masato
authors.initials: M
authors.lastname: Yamazaki
authors.forename: Tohru
authors.initials: T
authors.lastname: Tezuka
authors.forename: Tomohiro
authors.initials: T
authors.lastname: Takenoue
authors.forename: Chihiro
authors.initials: C
authors.lastname: Kosugi
authors.forename: Ryota
authors.initials: R
authors.lastname: Higuchi
authors.forename: Shiho
authors.initials: S
authors.lastname: Yamamoto
authors.forename: Yoshihisa
authors.initials: Y
authors.lastname: Watayo
authors.forename: Yohsuke
authors.initials: Y
authors.lastname: Yagawa
authors.forename: Masato
authors.initials: M
authors.lastname: Suzuki
mesh_terms: D000328:Adult; D000970:Antineoplastic Agents / Q000494:pharmacology; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage / Q000627:therapeutic use*; D003113:Colonoscopy / Q000379:methods; D015179:Colorectal Neoplasms / Q000188:drug therapy* / Q000473:pathology*; D003287:Contrast Media / Q000494:pharmacology; D005472:Fluorouracil / Q000008:administration & dosage; D006801:Humans; D002955:Leucovorin / Q000008:administration & dosage; D008113:Liver Neoplasms / Q000188:drug therapy* / Q000556:secondary*; D008297:Male; D009362:Neoplasm Metastasis; D009944:Organoplatinum Compounds / Q000008:administration & dosage; D011379:Prognosis; D012074:Remission Induction; D013997:Time Factors; D014057:Tomography, X-Ray Computed / Q000379:methods; D016896:Treatment Outcome
chemical_list: D000970:Antineoplastic Agents; D003287:Contrast Media; D009944:Organoplatinum Compounds; D002955:Leucovorin; D005472:Fluorouracil